Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

References

• Hosford SR, Miller TW. Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, src, JAK/ STAT,PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med. 2014;7:203–215.
   PubMedGoogle Scholar
• Platet N, Cathiard AM, Gleizes M, et al. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol. 2004;51(1):55–67.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast. 2017;31:244–259.
   PubMed Web of Science ®Google Scholar
• NCCN Clinical Practice Guidelines in Oncology. Breast Cancer, version 2 [Internet]. Fort Washington (PA): National Comprehensive Cancer Network; 2017 Apr 6 [cited 2017 Jul 18]. Available from: http://www.nccn.org
   Google Scholar
• Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011;121(10):3797–3803.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247.
   PubMed Web of Science ®Google Scholar
• Nardone A, De Angelis C, Trivedi MV, et al. The changing role of ER in endocrine resistance. Breast. 2015;24(Suppl. 2):S60–S66.
   PubMedGoogle Scholar
• Johnson A, Skotheim JM. Start and the restriction point. Curr Opin Cell Biol. 2013;25(6):717–723.
   PubMed Web of Science ®Google Scholar
• Murphy CG, Dickler MN. The role of CDK4/6 inhibition in breast cancer. Oncologist. 2015;20(5):483–490.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23(13):3251–3262.
   PubMed Web of Science ®Google Scholar
• Thangavel C, Dean JL, Ertel A, et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011;18(3):333–345.
   PubMed Web of Science ®Google Scholar
• Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar
• IBRANCE® (palbociclib) Prescribing Information [Internet]. New York (NY): Pfizer Laboratories, Division of Pfizer Inc; 2015 [cited 2017 Jul 18]. Available from: http://www.labeling.pfizer.com/ShowLabeling.aspx?id=2191
   Google Scholar
• KISQALI® (ribociclib) prescribing information [Internet]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2017 [cited 2017 Jul 18]. Available from: http://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/kisqali_copack.pdf
   Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22(9):1605–1613.
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21(11):2101–2109.
   PubMed Web of Science ®Google Scholar
• Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26(30):4883–4890.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–529.
   PubMed Web of Science ®Google Scholar
• Chen P, Lee NV, Hu W, et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol Cancer Ther. 2016;15(10):2273–2281.
   PubMed Web of Science ®Google Scholar
• Infante J,R Cassier PA, Gerecitano JF, et al. A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2016;22(23):5696–5705.
   PubMed Web of Science ®Google Scholar
• Dhuria SV, Siddani R, Kosecki CM, et al. A phase I food-effect study of the ribociclib (LEE011) drug-in-capsule (DiC) formulation in healthy subjects. J Clin Oncol. 2015;33(15 Suppl.):Abstracte 13577.
   Web of Science ®Google Scholar
• Rader J, Russell MR, Hart LS, et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173–6182.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Criscitiello C, Esposito A, et al. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opin Drug Metab Toxicol. 2017;13(5):575–581.
   PubMed Web of Science ®Google Scholar
• Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014;13(9):2184–2193.
   PubMed Web of Science ®Google Scholar
• Kim S, Loo A, Chopra R, et al. LEE011: an orally bioavailable, selective small molecule inhibitor of CDK4/6–reactivating rb in cancer. AACR-NCI-EORTC International Conference. Mol Cancer Ther. 2013;12(Suppl.11):Abstract PR02.
   Google Scholar
• O’Brien N, Di Tomaso E, Ayala R, et al. In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer. AACR. Cancer Res. 2014;74(Suppl. 19):Abstract 4756.
   Web of Science ®Google Scholar
• Yamada Y, Ishikawa N, Kakizume T, et al. A phase I study of single-agent ribociclib in japanese patients with advanced solid tumors. AACR-NCI-EORTC International Conference. Mol Cancer Ther. 2015;14(12 Suppl. 2):Abstract B31.
   Google Scholar
• Spring LM, Zangardi ML, Moy B, et al. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22(9):1039–1048.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 2 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Munster P, Ismail-Khan R, Garcia-Estevez L, et al. Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer. SABCS. Cancer Res. 2017;77(Suppl.4):Abstract P4-22-18.
   Google Scholar
• Oliveira M, Chavez-MacGregor M, Modi S, et al. Adding ribociclib to everolimus and exemestane in ER+/HER2– advanced breast cancer: feasibility and possible benefits. CoBrCa. 2016;Abstract O7.
   Google Scholar
• Curigliano G, Gómez Pardo P, Meric-Bernstam F, et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast. 2016;28:191–198.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). ESMO. Ann Oncol. 2016;27(Suppl. 6):Abstract LBA1_PR.
   PubMedGoogle Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. ASCO. J Clin Oncol. 2017;35(15 Suppl.):Abstract 1038.
   Google Scholar
• Burris HA, Chan A, Campone M, et al. First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial. SABCS. Cancer Res. 2017;77(Suppl. 4):Abstract P4-22-16.
   Google Scholar
• Conte P, Paluch-Shimon S, Burris HA, et al. First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) who received prior (neo)adjuvant therapy: a subgroup analysis of the MONALEESA-2 trial. SG-BCC. Breast. 2017;32:S70.
   Web of Science ®Google Scholar
• O’Shaughnessy J, Petrakova K, Sonke GS, et al. First-line ribociclib plus letrozole in patients with de novo HR+, HER2– ABC: a subgroup analysis of the MONALEESA-2 trial. SABCS. Cancer Res. 2016;77(Suppl.4):Abstract P4-22-05.
   Google Scholar
• Sonke GS, Hart LL, Campone M, et al. Efficacy and safety of ribociclib + letrozole in elderly patients with HR+, HER2– advanced breast cancer in MONALEESA-2. ECCO. Eur J Cancer. 2017;72(Suppl. 2):Abstract 2LBA.
   Google Scholar
• Verma S, Gil-Gil M, Hegg R, et al. Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with HR+, HER2– advanced breast cancer and a high disease burden. IMPAKT. Ann Oncol. 2017;28(Suppl. 1):Abstract 19P.
   Google Scholar
• Yap YS, Tseng LM, Blackwell KL, et al. First-line ribociclib + letrozole in postmenopausal Asian women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): a subgroup analysis from MONALEESA-2. ESMO Asia. Ann Oncol. 2016;27(Suppl. 9):Abstract LBA1_PR.
   Google Scholar
• Janni W, Burris HA, Blackwell K, et al. First-line ribociclib + letrozole for postmenopausal women with HR+, HER2– ABC: MONALEESA-2 safety results. ASCO. J Clin Oncol. 2017;35(Suppl.15):Abstract 1047.
   Google Scholar
• Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34(25):3069–3103.
   PubMed Web of Science ®Google Scholar
• Verma S, O’Shaughnessy J, Burris HA, et al. Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) treated with ribociclib + letrozole: results from MONALEESA-2. ASCO. J Clin Oncol. 2017;35(Suppl.15):Abstract 1020.
   Google Scholar
• Janni W, Alba E, Bachelot T, et al. Duration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– advanced breast cancer. ESMO. Ann Oncol. 2017;28(Suppl. 5):Abstract 245PD.
   Google Scholar
• André F, Stemmer SM, Campone M, et al. Ribociclib + letrozole for first-line treatment of HR+, HER2– advanced breast cancer: Efficacy by baseline tumor markers. AACR. Cancer Res. 2017;77(13 Suppl.):Abstract CT045.
   Google Scholar
• Tripathy D, Bardia A, Hurvitz S, et al. A phase III, double-blind, placebo-controlled evalutation of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-7. MBCC. 2016;Abstract 343.
   Google Scholar
• Study of efficacy and safety of LEE011 in men and postmenopausal women with advanced breast cancer (MONALEESA-3) [Internet]. ClinicalTrials.gov; 2015 Apr 1 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02422615
   Google Scholar
• Study for women and men with hormone-receptor positive locally advanced or metastatic breast cancer (RIBECCA) [Internet]. ClinicalTrials.gov; 2017 Mar 10 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03096847
   Google Scholar
• Study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with HR+ HER2– aBC [Internet]. ClinicalTrials.gov; 2016 Oct 21 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02941926
   Google Scholar
• Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7) [Internet]. ClinicalTrials.gov; 2014 Oct 22 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02278120
   Google Scholar
• Tripathy D, Sohn J, Im S-A, et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the randomized phase III MONALEESA-7 trial. SABCS. 2017:Abstract GS2–05.
   Google Scholar
• Fasching PA, Jerusalem G, Pivot X, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of men and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who have received no or only one line of prior endocrine treatment: MONALEESA-3. ASCO. J Clin Oncol. 2016;76(4 Suppl.):Abstract TPS624.
   Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: efficacy and safety updates with longer follow-up across patient subgroups. SABCS. 2017;Abstract P5-21-03.
   Google Scholar
• Cristofanilli M, DeMichele A, Giorgetti C, et al. Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3. J Clin Oncol. 2017;35:Abstract 1050.
   Web of Science ®Google Scholar
• Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+, HER– advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• VERZENIO™ (abemaciclib) prescribing information [Internet]. Indianapolis (IN): Eli Lilly and Company; 2017 [cited 2017 Dec 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208716s000lbl.pdf
   Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825–837.
   PubMed Web of Science ®Google Scholar
• Tiedt R, Delach S, Kovats S, et al. Preclinical selectivity profile of the CDK4/6 inhibitor ribociclib compared with that of palbociclib and abemaciclib. AACR. Cancer Res. 2017;77(13 Suppl.):Abstract 2346.
   Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6:740–753.
   PubMed Web of Science ®Google Scholar
• Shapiro G, Rosen LS, Tolcher AW, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. J Clin Oncol. 2013;31(Suppl.15):Abstract 2500.
   Google Scholar
• Novartis. Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2– metastatic breast cancer in combination with any aromatase inhibitor [Internet]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2017 [cited 2018 Jan 5]. Available from: https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-lee011-receives-fda-approval-first-line-treatment
   Google Scholar
• Novartis. Novartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2– locally advanced or metastatic breast cancer in combination with any aromatase inhibitor [Internet]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2017 [cited 2018 Jan 5]. Available from: https://www.novartis.com/news/media-releases/novartis-kisqalir-ribociclib-receives-eu-approval-first-line-treatment-hrher2
   Google Scholar
• Novartis. Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2– advanced breast cancer [Internet]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2018 [cited 2018 Jan 5]. Available from: https://www.novartis.com/news/media-releases/novartis-kisqalir-received-fda-breakthrough-therapy-designation-initial-endocrine-based-treatment-premenopausal-women-hrher2-advanced-breast-cancer
   Google Scholar
• Juric D, Campone M, Munster P, et al. Ribociclib + endocrine therapy doublet combinations in HR+, HER2- advanced breast cancer: phase I clinical activity and impact of molecular alterations. AACR. Cancer Res. 2017;77(13 Suppl.):Abstract CT087.
   Google Scholar
• LEE011 for patients with CDK4/6 pathway activated tumors (SIGNATURE) [Internet]. ClinicalTrials.gov; 2014 Jul 9 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02187783
   Google Scholar
• Yang C, Li Z, Bhatt T, et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene. 2017;36(16):2255–2264.
   PubMed Web of Science ®Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301–2313.
   PubMed Web of Science ®Google Scholar
• Jansen VM, Bhola NE, Bauer JA, et al. Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer. Cancer Res. 2017;77(9):2488–2499.
   PubMed Web of Science ®Google Scholar
• Dean JL, Thangavel C, McClendon AK, et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010;29(28):4018–4032.
   PubMed Web of Science ®Google Scholar
• Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012;287(34):29075–29087.
   PubMed Web of Science ®Google Scholar
• Ertel A, Dean JL, Rui H, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle. 2010;9(20):4153–4163.
   PubMed Web of Science ®Google Scholar
• Dall’Acqua A, Sonego M, Pellizzari I, et al. CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation. EMBO Mol Med. 2017;9(10):1415–1433.
   PubMed Web of Science ®Google Scholar
• Wang H, Nicolay BN, Chick JM, et al. The metabolic function of cyclin D3–CDK6 kinase in cancer cell survival. Nature. 2017;546(7658):426–430.
   PubMed Web of Science ®Google Scholar
• A trial of ribocilcib (LEE011) and weekly paclitaxel in patients with Rb+ advanced breast cancer [Internet]. ClinicalTrials.gov; 2015 Nov 5 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02599363
   Google Scholar
• Phase I evaluating the combination of Ribociclib+Capecitabine in locally advanced/metastatic breast cancer HER2 negative (GEP14-LEECAP) [Internet]. ClinicalTrials.gov; 2016 Feb 19 [cited 2017 Jul 18]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT002754011
   Google Scholar
• Aleem E, Arceci RJ. Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol. 2015;3:16.
   PubMed Web of Science ®Google Scholar